🇺🇸 FDA

Company profile · Sponsor

Crinetics

Crinetics Pharmaceuticals Europe GmbH

CRNX · NYSE pharma SAN DIEGO, CA, EU
Pipeline
12
Drugs
2
Patents
8

Quick answer

Crinetics (CRNX) is a pharma company. headquartered in SAN DIEGO, CA, EU. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker CRNX
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, EU
SEC CIK 0001658247

Pipeline (12)

Search pipeline →

  1. Atumelnant

    Crinetics

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    2 trials

  2. Paltusotine

    Crinetics

    Carcinoid Syndrome

    phase 3 small molecule active

    1 trial

  3. Paltusotine

    Crinetics

    Acromegaly

    phase 3 small molecule active

    5 trials

  4. CRN09682

    Crinetics

    SST2-positive Neuroendocrine Neoplasms

    phase 2 small molecule active

    1 trial

  5. Randomized: 40 mg Paltusotine

    Crinetics

    Carcinoid Syndrome

    phase 2 small molecule completed

    1 trial

  6. atumelnant

    Crinetics

    Cushing Syndrome

    phase 2 small molecule active

    1 trial

  7. atumelnant (CRN04894)

    Crinetics

    Congenital Adrenal Hyperplasia

    phase 2 small molecule active

    2 trials

  8. Atumelnant

    Crinetics

    Healthy Volunteers

    phase 1 small molecule active

    2 trials

  9. CRN00808

    Crinetics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. CRN01941 Oral Solution

    Crinetics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  11. CRN04894 Oral Solution

    Crinetics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. [14C]-CRN00808

    Crinetics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. paltusotine

    PALSONIFY

    H01CB06

  2. paltusotine hydrochloride

    PALSONIFY

    ORAL approved

Patents (8)

Search patents →

  1. US 12280046

    Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957674

    Formulations of a somatostatin modulator

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11834462

    Somatostatin modulators and uses thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11773076

    Crystalline forms of a somatostatin modulator

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11608335

    Somatostatin modulators and uses thereof

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11566015

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Crinetics?

Crinetics (CRNX) is a pharma company. headquartered in SAN DIEGO, CA, EU. listed on NYSE. NovaPharmaNews links 12 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Crinetics sponsor?

We track 12 ClinicalTrials.gov-linked programs for Crinetics, including Atumelnant and 11 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Crinetics company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.